Boston Scientific Corporation (FRA:BSX)
Germany · Delayed Price · Currency is EUR 77.20
+0.20 (0.26%)
At close: Jan 30, 2026
Boston Scientific Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 19,349 | 16,747 | 14,240 | 12,682 | 11,888 | 9,913 | |
Revenue Growth (YoY) | 21.61% | 17.61% | 12.29% | 6.68% | 19.92% | -7.66% |
Cost of Revenue | 6,128 | 5,290 | 4,391 | 4,003 | 3,760 | 3,242 |
Gross Profit | 13,221 | 11,457 | 9,849 | 8,679 | 8,128 | 6,671 |
Selling, General & Admin | 6,665 | 5,984 | 5,190 | 4,520 | 4,359 | 3,787 |
Research & Development | 1,942 | 1,615 | 1,414 | 1,323 | 1,204 | 1,143 |
Amortization of Goodwill & Intangibles | 894 | 856 | 828 | 803 | 741 | 789 |
Operating Expenses | 9,501 | 8,455 | 7,432 | 6,646 | 6,304 | 5,719 |
Operating Income | 3,720 | 3,002 | 2,417 | 2,033 | 1,824 | 952 |
Interest Expense | -339 | -305 | -265 | -470 | -341 | -361 |
Interest & Investment Income | 107 | 107 | 22 | 10 | 4 | 3 |
Currency Exchange Gain (Loss) | -17 | -16 | -41 | -31 | -27 | -32 |
Other Non Operating Income (Expenses) | -114 | -30 | -15 | -14 | -7 | 6 |
EBT Excluding Unusual Items | 3,357 | 2,758 | 2,118 | 1,528 | 1,453 | 568 |
Merger & Restructuring Charges | -89 | -16 | -69 | -24 | -40 | -179 |
Impairment of Goodwill | - | - | - | - | - | -73 |
Gain (Loss) on Sale of Investments | -62 | -79 | -59 | -1 | 250 | 383 |
Gain (Loss) on Sale of Assets | - | - | - | -22 | 78 | - |
Asset Writedown | -156 | -386 | -58 | -132 | -370 | -452 |
Legal Settlements | - | - | 111 | -173 | -430 | -278 |
Other Unusual Items | 220 | 5 | -58 | -35 | 136 | -49 |
Pretax Income | 3,270 | 2,282 | 1,985 | 1,141 | 1,077 | -80 |
Income Tax Expense | 486 | 436 | 393 | 443 | 36 | 2 |
Earnings From Continuing Operations | 2,784 | 1,846 | 1,592 | 698 | 1,041 | -82 |
Minority Interest in Earnings | 8 | 8 | 1 | - | - | - |
Net Income | 2,792 | 1,854 | 1,593 | 698 | 1,041 | -82 |
Preferred Dividends & Other Adjustments | 1 | 1 | 23 | 56 | 56 | 33 |
Net Income to Common | 2,791 | 1,853 | 1,570 | 642 | 985 | -115 |
Net Income Growth | 55.72% | 16.38% | 128.22% | -32.95% | - | - |
Shares Outstanding (Basic) | 1,478 | 1,472 | 1,453 | 1,431 | 1,422 | 1,417 |
Shares Outstanding (Diluted) | 1,493 | 1,486 | 1,464 | 1,440 | 1,434 | 1,417 |
Shares Change (YoY) | 0.71% | 1.53% | 1.65% | 0.41% | 1.21% | 0.43% |
EPS (Basic) | 1.89 | 1.26 | 1.08 | 0.45 | 0.69 | -0.08 |
EPS (Diluted) | 1.87 | 1.25 | 1.07 | 0.45 | 0.69 | -0.08 |
EPS Growth | 54.68% | 16.82% | 138.42% | -34.96% | - | - |
Free Cash Flow | 3,824 | 2,645 | 1,792 | 938 | 1,316 | 1,132 |
Free Cash Flow Per Share | 2.56 | 1.78 | 1.22 | 0.65 | 0.92 | 0.80 |
Gross Margin | 68.33% | 68.41% | 69.16% | 68.44% | 68.37% | 67.30% |
Operating Margin | 19.23% | 17.93% | 16.97% | 16.03% | 15.34% | 9.60% |
Profit Margin | 14.42% | 11.06% | 11.03% | 5.06% | 8.29% | -1.16% |
Free Cash Flow Margin | 19.76% | 15.79% | 12.58% | 7.40% | 11.07% | 11.42% |
EBITDA | 5,071 | 4,271 | 3,613 | 3,169 | 2,917 | 2,075 |
EBITDA Margin | 26.21% | 25.50% | 25.37% | 24.99% | 24.54% | 20.93% |
D&A For EBITDA | 1,351 | 1,269 | 1,196 | 1,136 | 1,093 | 1,123 |
EBIT | 3,720 | 3,002 | 2,417 | 2,033 | 1,824 | 952 |
EBIT Margin | 19.23% | 17.93% | 16.97% | 16.03% | 15.34% | 9.60% |
Effective Tax Rate | 14.86% | 19.11% | 19.80% | 38.82% | 3.34% | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.